You are here

Article info

Article menu
Download PDFPDF
Special communication
FDA’s reduced exposure marketing order for IQOS: why it is not a reliable global model

Authors

  1. Correspondence to Lauren Kass Lempert, Center for Tobacco Control Research & Education, UCSF, San Francisco, CA 94143, USA; Lauren.Lempert{at}ucsf.edu
View Full Text

Citation

Lempert LK, Bialous S, Glantz S
FDA’s reduced exposure marketing order for IQOS: why it is not a reliable global model
Tobacco Control 2022;31:e83-e87.

Publication history

  • Received October 20, 2020
  • Revised January 20, 2021
  • Accepted February 2, 2021
  • First published April 2, 2021.
Online issue publication 
July 22, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.